Endpoints News
Lilly to pay $1.2B for Ventyx Read in browser
Endpoints News
Thank you for reading, dupa dupackia!
basic
UPGRADE
M T W Thu F
8 January, 2026
sponsored by EpiCypher
Decode Chromatin Regulation to Inform Drug Mechanism, Resistance, and Strategy
Reliable readouts of transcriptional regulatory mechanisms enable researchers to decode drug mechanism of action, detect emerging resistance, and design mitigation strategies earlier in development. EpiCypher can accelerate your research with industry-validated CUT&RUN, DNA Methylation, and Fiber-seq Services to assess target engagement, transcription factor occupancy, chromatin accessibility, and epigenetic changes. Generate reproducible epigenomic data that informs target biology, MoA, and biomarker strategy.
Learn More
spotlight
Thursday at 1 pm: Fewer drugs, more chaos — a year under the new FDA
ENDPOINTS NEWS
news
Lilly to pay $1.2B for Ventyx and its NLRP3 drugs
ENDPOINTS NEWS
Exclusive: Charles Fuchs departs Roche for Tubulis' ADC pipeline fueled by recent $401M Series C
ENDPOINTS NEWS
Exclusive: GSK to pay $50M to use Noetik's AI cancer models
ENDPOINTS NEWS
Biotechs raise $700M+
Parabilis gets $305M for quest to conquer ‘undruggable’ proteins after early success
ENDPOINTS NEWS
Diagonal Therapeutics secures $125M to start first-in-human genetic disease trial
ENDPOINTS NEWS
Former Genentech leaders’ protein degrader startup nets $107M
ENDPOINTS NEWS
Beacon adds $75M in push to succeed where J&J vision treatment failed
ENDPOINTS NEWS
Vizgen raises $48M to propel push in spatial biology and multiomics tools
ENDPOINTS NEWS
Exclusive: An MIT trio built some of biotech’s favorite AI models. Now, they're building a business
ENDPOINTS NEWS
Exclusive: French biotech Enodia gets €20.7M co-led by Pfizer for protein degrader work
ENDPOINTS NEWS
ENDPOINTS at #JPM26
Biopharma’s year doesn’t start on January 1. It starts in San Francisco. Join Endpoints for bold conversations with the leaders shaping what's next. Plus, get access to the Endpoints Hub — our premium meeting space just steps from the action. Reserve your in-person or free virtual pass today.
in case you missed it
1.
FDA in 2025 holds fewest number of adcomms since the pandemic
ENDPOINTS NEWS
2.
Immuneering’s pancreatic cancer pill continues to beat standard care, updated first line data show
ENDPOINTS NEWS
3.
Ex-2seventy bio CEO Chip Baird leads immunology startup, with $50M to tackle IgE
ENDPOINTS NEWS
4.
Lux Capital raises $1.5B for its ninth fund
ENDPOINTS NEWS
5.
Exclusive: Lilly partners with protein mapping startup InduPro for up to $950M
ENDPOINTS NEWS
6.
GSK, Ionis say they may have a cure for some hepatitis B patients after Phase 3 win
ENDPOINTS NEWS
7.
News Briefing
BridgeBio shares KRAS data; Hutchmed's Phase 3 success in China
ENDPOINTS NEWS
8.
Exclusive: Meanwell and Maraganore get $80M for cardio prevention biotech Corsera
ENDPOINTS NEWS
9.
Exclusive: Relation, Deerfield agree to form new companies from discovered drug targets
ENDPOINTS NEWS